TrialScope Turns to NOL Program, Venture Fund Investment

June 24, 2019

As seen on NJEDA.com - Posted June 24, 2019 - Original Article


TRENTON, NJ (June 24, 2019) – A combination of resources from the New Jersey Economic Development Authority (NJEDA), a growth equity investment from three venture capital firms including Edison Partners, and proximity to numerous global pharmaceutical giants has helped Hudson County-based TrialScope support pharmaceutical companies conducting clinical trials around the world.


Operating out of an office in Jersey City, TrialScope helps pharmaceutical companies through the clinical-trial regulatory approvals process. 

Continued on NJEDA.com

Previous Article
As Precision Medicine Grows, So Does the Value of Trial Diversity
As Precision Medicine Grows, So Does the Value of Trial Diversity

Industry experts, including TrialScope CEO Jeff Kozloff, reflect on the recent FDA guidance designed to imp...

Next Article
 FDA addresses lack of diversity in clinical trials in draft guidance
FDA addresses lack of diversity in clinical trials in draft guidance

In a bid to increase clinical trial diversity, the FDA published a draft guidance for sponsors. TrialScope ...